Gri Bio, INC Form 4 insider transactions

Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.

NASDAQ
GRI Bio, Inc.'s Chief Financial Officer, Leanne Kelly, was granted 43,222 stock options with an exercise price of $1.93.
NASDAQ
GRI Bio, Inc. Director David Leslie Szekeres was granted 39,897 stock options with an exercise price of $1.93, vesting over one year.
NASDAQ
GRI Bio, Inc. Director David Charles Baker was granted 23,605 stock options with an exercise price of $1.93, vesting over one year.
NASDAQ
GRI Bio, Inc. Director Camilla V Simpson received a grant of 23,605 stock options with an exercise price of $1.93, vesting over one year.
NASDAQ
Vipin Chaturvedi, Chief Scientific Officer of GRI Bio, Inc., reports the acquisition of stock options.
NASDAQ
GRI Bio, Inc. Director Roelof Rongen was granted 23,605 stock options with an exercise price of $1.93, vesting over one year.
NASDAQ
GRI Bio, Inc. CEO Walter Marc Hertz was granted 103,067 stock options with an exercise price of $1.93, vesting over three years.
NASDAQ
GRI Bio, Inc. CEO Walter Marc Hertz was granted 26,688 stock options with an exercise price of $1.41, vesting over three years.
NASDAQ
GRI Bio, Inc. Director David Leslie Szekeres was granted 10,276 stock options with an exercise price of $1.41, vesting over one year.
NASDAQ
GRI Bio, Inc. Director David Charles Baker was granted 5,994 stock options with an exercise price of $1.41, vesting over one year.
NASDAQ
GRI Bio, Inc. Director Roelof Rongen was granted 5,994 stock options with an exercise price of $1.41, vesting over one year.
NASDAQ
GRI Bio's Chief Scientific Officer, Vipin Chaturvedi, was granted 11,854 stock options with an exercise price of $1.41.
NASDAQ
GRI Bio, Inc. Director Camilla Simpson was granted 5,994 stock options with an exercise price of $1.41, vesting over one year.
NASDAQ
GRI Bio, Inc.'s Chief Financial Officer, Leanne Kelly, was granted 11,854 stock options with an exercise price of $1.41, effective August 26, 2025.
NASDAQ
GRI Bio, Inc. director Camilla V. Simpson was granted 4,527 stock options with a $1.3 exercise price, vesting quarterly over one year.
NASDAQ
GRI Bio, Inc. Director David Charles Baker was granted 4,527 stock options with an exercise price of $1.30, effective August 13, 2025.
NASDAQ
GRI Bio, Inc. Director Roelof Rongen was granted 4,527 stock options with an exercise price of $1.30, vesting over one year.
NASDAQ
GRI Bio, Inc. Director David Leslie Szekeres was granted 7,545 stock options with an exercise price of $1.3, vesting over one year.
NASDAQ
GRI Bio's Chief Financial Officer, Leanne Kelly, acquired 43,319 stock options at an exercise price of $0.6857 on January 23, 2025.
NASDAQ
GRI Bio's Chief Scientific Officer, Vipin Chaturvedi, acquired 43,319 stock options at an exercise price of $0.6857 on January 23, 2025.
NASDAQ
GRI Bio's CEO, Walter Marc Hertz, acquired 129,730 stock options at an exercise price of $0.6857 on January 23, 2025.
NASDAQ
Camilla V. Simpson, a director at GRI Bio, Inc., acquired 30,297 stock options on January 23, 2025.
NASDAQ
David Charles Baker, a director at GRI Bio, Inc., acquired 30,297 shares through stock options at a price of $0.6857 per share.
NASDAQ
David Leslie Szekeres, a director at GRI Bio, Inc., acquired 51,937 stock options on January 23, 2025.
NASDAQ
A director of GRI Bio, Inc. has acquired over 30,000 stock options as part of a pre-arranged trading plan.